These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11036114)

  • 1. Patient preferences for axillary dissection in the management of early-stage breast cancer.
    Galper SR; Lee SJ; Tao ML; Troyan S; Kaelin CM; Harris JR; Weeks JC
    J Natl Cancer Inst; 2000 Oct; 92(20):1681-7. PubMed ID: 11036114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
    Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
    J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sentinel lymph node biopsy in breast cancer New indications and our experience.
    Zanghì G; Rinzirillo NM; Caponnetto AM; Vecchio R; Catania V; Leanza V
    Ann Ital Chir; 2015; 86():508-12. PubMed ID: 26898363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the value of axillary dissection or sentinel node biopsy in patients with ductal carcinoma in situ?
    Mabry H; Giuliano AE; Silverstein MJ
    Am J Surg; 2006 Oct; 192(4):455-7. PubMed ID: 16978948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ.
    Coromilas EJ; Wright JD; Huang Y; Feldman S; Neugut AI; Chen L; Hershman DL
    JAMA Oncol; 2015 Jun; 1(3):323-32. PubMed ID: 26181180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients.
    Verheuvel NC; Voogd AC; Tjan-Heijnen VC; Roumen RM
    Eur J Surg Oncol; 2016 Aug; 42(8):1162-8. PubMed ID: 27265036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal management of ductal carcinoma in situ of the breast.
    Sakorafas GH; Farley DR
    Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International variation in management of screen-detected ductal carcinoma in situ of the breast.
    Ponti A; Lynge E; James T; Májek O; von Euler-Chelpin M; Anttila A; Fitzpatrick P; Mano MP; Kawai M; Scharpantgen A; Fracheboud J; Hofvind S; Vidal C; Ascunce N; Salas D; Bulliard JL; Segnan N; Kerlikowske K; Taplin S;
    Eur J Cancer; 2014 Oct; 50(15):2695-704. PubMed ID: 25149183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.
    Sakorafas GH; Tsiotou AG
    Cancer Treat Rev; 2000 Apr; 26(2):103-25. PubMed ID: 10772968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Surgical treatment and prognosis of ductal carcinoma in situ: 526 cases analysis].
    Zhu SJ; Chen XS; Wu JY; Huang O; He JR; Zhu L; Chen WG; Li YF; Fei XC; Shen KW
    Zhonghua Wai Ke Za Zhi; 2017 Feb; 55(2):114-119. PubMed ID: 28162210
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment Intensity Differences After Early-Stage Breast Cancer (ESBC) Diagnosis Depending on Participation in a Screening Program.
    Elder K; Nickson C; Pattanasri M; Cooke S; Machalek D; Rose A; Mou A; Collins JP; Park A; De Boer R; Phillips C; Pridmore V; Farrugia H; Bruce Mann G
    Ann Surg Oncol; 2018 Sep; 25(9):2563-2572. PubMed ID: 29717421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive versus negative sentinel nodes in early breast cancer patients: axillary or loco-regional relapse and survival. A study spanning 2000-2012.
    García Fernández A; Chabrera C; García Font M; Fraile M; Lain JM; Barco I; González C; Gónzalez S; Reñe A; Veloso E; Cassadó J; Pessarrodona A; Giménez N
    Breast; 2013 Oct; 22(5):902-7. PubMed ID: 23684000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axillary evaluation and lymphedema in women with ductal carcinoma in situ.
    Coromilas EJ; Wright JD; Huang Y; Feldman S; Neugut AI; Hillyer GC; Chen L; Hershman DL
    Breast Cancer Res Treat; 2016 Jul; 158(2):373-84. PubMed ID: 27365080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of a prior diagnosis of DCIS on survival from invasive breast cancer.
    Sopik V; Iqbal J; Sun P; Narod SA
    Breast Cancer Res Treat; 2016 Jul; 158(2):385-93. PubMed ID: 27383477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial axillary lymph node dissection inferior to the intercostobrachial nerves complements sentinel node biopsy in patients with clinically node-negative breast cancer.
    Li J; Jia S; Zhang W; Qiu F; Zhang Y; Gu X; Xue J
    BMC Surg; 2015 Jun; 15():79. PubMed ID: 26123412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Sentinel Lymph Node Biopsy and Factors Associated with Invasion in Extensive DCIS of the Breast Treated by Mastectomy: The Cinnamome Prospective Multicenter Study.
    Tunon-de-Lara C; Chauvet MP; Baranzelli MC; Baron M; Piquenot J; Le-Bouédec G; Penault-Llorca F; Garbay JR; Blanchot J; Mollard J; Maisongrosse V; Mathoulin-Pélissier S; MacGrogan G
    Ann Surg Oncol; 2015 Nov; 22(12):3853-60. PubMed ID: 25777085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous breast and axillary recurrence in a patient with a history of breast cancer and ipsilateral upper extremity melanoma: challenges in diagnosis and management.
    Ross M; Hadzikadic Gusic L; Dabbs DJ; Kelley J; Diego E
    Tumori; 2014; 100(4):136e-9e. PubMed ID: 25296604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
    Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
    Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.